TRuC-T Cell Development Services

Q: Are TRuC-T cells safer regarding Cytokine Release Syndrome (CRS)?

While clinical trials are ongoing, in vitro and in vivo data show that TRuC-T cells produce significantly lower levels of IL-2, IFN gamma, and TNF alpha compared to CAR-T cells, suggesting a lower risk of CRS.

Online Inquiry

Background Service What We Can Offer Workflow Specialty Services Highlights FAQs Contact

Creative Biolabs provides TRuC-T Cell Therapy Development Services to overcome the intrinsic limitations of conventional CAR-T therapies, including excessive cytokine release, tonic signaling driven T cell exhaustion, and limited efficacy against solid tumors. These services enable the development of highly potent and physiologically regulated T cell therapeutics by integrating antibody-based binding domains directly into the full T cell receptor complex. Through advanced protein engineering, Creative Biolabs preserves the native TCR signaling architecture, thereby enhancing anti-tumor activity while improving clinical safety and therapeutic consistency.

Introduction

TRuC-T cell therapy is a breakthrough technology that reprograms the intact T cell receptor complex for HLA-independent tumor recognition. By fusing antibody-based domains to TCR subunits, TRuCs leverage the complete signaling capacity of the TCR, including 10 ITAM motifs. TRuCs are particularly effective, showing superior tumor clearance in disseminated and solid tumor xenograft models compared to second-generation CAR-T cells, all while maintaining a more favorable cytokine profile.

Fig.1 Native TCR complexes, along with five TCR complexes engineered to contain TRuCs. (Creative Biolabs Original) Fig.1 Native TCR complexes as well as five TRuC containing TCR complexes.

Service

Creative Biolabs provides comprehensive end-to-end solutions for the design, construction, and validation of T cell receptor fusion constructs (TRuCs). Unlike standard CARs that rely on isolated CD3 zeta chains, our service integrates your target-specific binders, such as scFv, directly into the N-termini of endogenous TCR subunits (alpha, beta, gamma, delta, or epsilon). This enables your project to leverage the full signaling machinery of the TCR complex, resulting in more sensitive and controlled T cell activation.

Feasibility assessment for TRuC-based receptor architectures.
Construct a design and optimization for stable, controlled T-cell activation.
Engineered T-cell generation and expansion under research-grade workflows.
Functional profiling, including cytotoxicity, activation, and exhaustion risk indicators.
In vivo proof-of-concept models to support candidate selection.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Analysis of TRuC-T Cell Therapy Development. (Creative Biolabs Original)

Our Workflow

Required Starting Materials: To initiate the service, clients typically provide the target antigen sequence, existing binder sequences, and specific effector cell requirements.

Workflow of TRuC-T Cell Therapy Development. (Creative Biolabs Original)

Final Deliverables: Clients receive a comprehensive analytical report detailing transduction efficiency and surface expression levels, raw data from cytotoxicity and cytokine assays, and the validated TRuC-T cell constructs ready for further expansion or in vivo study.

Specialty Services

One-Stop Core TRuC-T Development

Creative Biolabs provides one-stop core TRuC-T development services covering receptor design, construct engineering, cell manufacturing, and functional validation, enabling rapid translation and enhanced antitumor activity for next-generation T cell therapies.

"Armored" & TME Penetration TRuC-T Development

We deliver armored and TME-penetrating TRuC-T development services, engineering cytokine-armored receptors and penetration strategies to overcome immunosuppression, enhance infiltration, persistence, and durable antitumor activity in solid tumors.

Core Benefits

Lower Cytokine Release: TRuC-T cells kill tumor cells as potently as second-generation CARs but with significantly lower release of pro-inflammatory cytokines, potentially offering a better safety profile in clinical settings.
Superior Solid Tumor Efficacy: Our platform has demonstrated robust activity in solid tumor models, including glioblastoma and mesothelin-positive cancers, where traditional CARs often fail.
MHC-Independent Targeting: While utilizing the TCR complex, TRuC-T cells operate in an HLA-independent manner, allowing for broader patient eligibility.

FAQs

Q1: How does TRuC-T cell signaling differ from standard CAR-T cells?

A1: Standard CARs use isolated CD3 zeta domains, whereas TRuCs engage the entire TCR complex, triggering phosphorylation of CD3 epsilon, gamma, and LAT, which provides a more comprehensive and physiologically regulated signal.

Q2: Can TRuCs be used for solid tumor targets?

A2: Yes. TRuCs have shown potent anti-tumor activity in glioblastoma and mesothelin models, potentially due to better tumor penetration and less exhaustion than traditional CAR-T cells.

Q3: What is the benefit of fusing the binder to the CD3 epsilon subunit?

A3: Fusing to CD3 epsilon allows for the integration of up to two binders per TCR complex, often leading to the highest surface expression and most stable cytolytic synapse.

Q4: Are TRuC-T cells safer regarding Cytokine Release Syndrome (CRS)?

A4: While clinical trials are ongoing, in vitro and in vivo data show that TRuC-T cells produce significantly lower levels of IL-2, IFN gamma, and TNF alpha compared to CAR-T cells, suggesting a lower risk of CRS.

Partner with Us

Choosing Creative Biolabs means accessing a platform that prioritizes physiological precision over "brute force" engineering. Creative Biolabs is committed to advancing the field of adoptive cell therapy through our high-performance TRuC-T Cell Therapy Development Services. By integrating physiological signaling with targeted potency, we help you overcome the hurdles of T cell exhaustion and cytokine toxicity. For detailed technical specifications or to discuss your specific project requirements, please contact our specialist team.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.